Article
J&J, Legend double CAR-T manufacturing investment to $500M as Carvykti eyes wider myeloma use
Rating:
0.0
Views:
78
Likes:
1
Library:
1
Manufacturing has constrained Legend Biotech and Johnson & Johnson's supply of their CAR-T therapy Carvykti to heavily pretreated multiple myeloma patients. | Manufacturing has constrained Legend Biotech and Johnson & Johnson's supply of their CAR-T therapy Carvykti to heavily pretreated multiple myeloma patients. As the drug targets earlier treatment—and larger markets—the partners have decided to literally double down on production.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value